agree with stardestroyer - a small step forward.
BUT no plans for clinical trials until second half of 2017, no dividend etc so this may be a LT hold but anything can still happen and risk still high.
Was this product being a JV with Hexima??? thought at some stage it may have been - wonder if the JV still on?
IMO lack of transparency may impact here as well as the perceived nonperforming situation of the company.
wonder if they will pay bonuses if they achieve the primary target of late 2017 clinical trials???
as in mitas post
"Key players of the global dermatophytic onychomycosis therapeutics market include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc." hmmm wonder what they will do to combat this if its successful? maybe we can sell it to them - only early days yet and going to be a long drawn out wait for ANN's if this is the only item on the go.
still hoping for a SP turnaround but am not seeing that in the short-medium term. anyhow it is a positive step that has been long awaited so hopefully the follow through will not disappoint!
Add to My Watchlist
What is My Watchlist?
